Expertise in
22
conditions

Dr. Melhem M. Solh

Internal Medicine
Blood & Marrow Transplant Group Of Georgia
5670 Peachtree Dunwoody Rd Ste 1000, 
Atlanta, GA 
Accepting New Patients
Offers Telehealth
17 Years of Experience
Expertise in
22
conditions
Blood & Marrow Transplant Group Of Georgia
5670 Peachtree Dunwoody Rd Ste 1000, 
Atlanta, GA 

Overview

Melhem Solh is a primary care provider, practicing in Internal Medicine in Atlanta, Georgia. He has been practicing medicine for over 17 years.

Dr. Solh is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Graft Versus Host Disease (GvHD), Bone Marrow Aspiration, and Bone Graft.

He is actively involved in clinical research, co-authoring 150 peer reviewed articles and participating in 7 clinical trials. Dr. Solh is currently accepting new patients.

Specialties

Internal Medicine

Licenses

Specialist in GA

Hospital Affiliations

Northside Hospital

Languages Spoken

English
Arabic

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Absolute Total Care South Carolina
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alliant Health
  • HMO
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Blood & Marrow Transplant Group of Georgia
5670 Peachtree Dunwoody Rd Ste 1000, Atlanta, GA 30342

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Phase II Trial Evaluating the Safety and Efficacy of Combined CD20- and BTK-Targeted B Cell Depleting Therapy With Rituximab and Ibrutinib in the Primary Treatment of Chronic Graft-Versus-Host Disease
Phase II Trial Evaluating the Safety and Efficacy of Combined CD20- and BTK-Targeted B Cell Depleting Therapy With Rituximab and Ibrutinib in the Primary Treatment of Chronic Graft-Versus-Host Disease
Enrollment Status: Terminated
Publish Date: December 13, 2024
Intervention Type: Drug
Study Drugs: Rituximab, Ibrutinib
Study Phase: Phase 2
A Phase II Study Evaluating the Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies
A Phase II Study Evaluating the Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies
Enrollment Status: Completed
Publish Date: November 07, 2023
Intervention Type: Drug, Procedure
Study Drugs: BL-8040 CD34-Positive Hematopoietic Cells, Hematopoietic Stem Cell Transplant
Study Phase: Phase 2
A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-2)
A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-2)
Enrollment Status: Completed
Publish Date: August 29, 2023
Intervention Type: Drug
Study Drug: Loncastuximab tesirine
Study Phase: Phase 2
Ph 1 Study of Escalating Single & Multiple Doses of Mana 312 (Multi Tumor-Associated Antigen T Cells) Administered to Adult Subjects With Acute Myeloid Leukemia or Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplant
Ph 1 Study of Escalating Single & Multiple Doses of Mana 312 (Multi Tumor-Associated Antigen T Cells) Administered to Adult Subjects With Acute Myeloid Leukemia or Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplant
Enrollment Status: Terminated
Publish Date: June 18, 2023
Intervention Type: Biological
Study Drug: Mana 312
Study Phase: Phase 1
Use of Convalescent Plasma Collected From Donors Recovered From COVID-19 Virus Disease for Transfusion, as an Empirical and Preemptive Treatment During Viral Pandemic Outbreak
Use of Convalescent Plasma Collected From Donors Recovered From COVID-19 Virus Disease for Transfusion, as an Empirical and Preemptive Treatment During Viral Pandemic Outbreak
Enrollment Status: Terminated
Publish Date: November 14, 2022
Intervention Type: Biological
Study Drug: Anti-COVID-19 Plasma
Study Phase: Phase 2
A Phase 1, Open-label, Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Activity of ADCT 301 in Patients With Relapsed or Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia
A Phase 1, Open-label, Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Activity of ADCT 301 in Patients With Relapsed or Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia
Enrollment Status: Terminated
Publish Date: February 26, 2020
Intervention Type: Drug
Study Phase: Phase 1
An Open-Label Phase 2 Prospective, Randomized, Controlled Study of CLT-008 Myeloid Progenitor Cells as a Supportive Care Measure During Induction Chemotherapy for Acute Myeloid Leukemia
An Open-Label Phase 2 Prospective, Randomized, Controlled Study of CLT-008 Myeloid Progenitor Cells as a Supportive Care Measure During Induction Chemotherapy for Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: September 27, 2018
Intervention Type: Biological
Study Phase: Phase 2
View 6 Less Clinical Trials

150 Total Publications

Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALL.
Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALL.
Journal: Blood advances
Published: April 09, 2026
Similar Doctors
Expertise in
38
conditions
Dr. Elliott F. Winton
Internal Medicine
Expertise in
38
conditions
Dr. Elliott F. Winton
Internal Medicine

Grady Memorial Hospital Corporation

80 Jesse Hill Jr Dr SE, 
Atlanta, GA 
 (9.0 miles away)
404-489-9000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Elliott Winton is a primary care provider, practicing in Internal Medicine in Atlanta, Georgia. Dr. Winton is highly rated in 38 conditions, according to our data. His clinical expertise encompasses Myelofibrosis, Essential Thrombocythemia, Polycythemia Vera, and Chronic Myelogenous Leukemia (CML). Dr. Winton is currently accepting new patients.

Expertise in
6
conditions
Dr. Paul T. Cantey
Internal Medicine
Expertise in
6
conditions
Dr. Paul T. Cantey
Internal Medicine

Grady Memorial Hospital Corporation

80 Jesse Hill Jr Dr SE, 
Atlanta, GA 
 (9.0 miles away)
404-616-4396
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Paul Cantey is a primary care provider, practicing in Internal Medicine in Atlanta, Georgia. Dr. Cantey is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Onchocerciasis, Childhood Volvulus, Spirurida Infections, and Secernentea Infections. Dr. Cantey is currently accepting new patients.

Expertise in
5
conditions
Dr. Inger K. Damon
Internal Medicine
Expertise in
5
conditions
Dr. Inger K. Damon
Internal Medicine

Office

1627 Clairmont Ln NE, 
Atlanta, GA 
 (4.8 miles away)
404-717-5167
Languages Spoken:
English

Inger Damon is a primary care provider, practicing in Internal Medicine in Atlanta, Georgia. Dr. Damon is highly rated in 5 conditions, according to our data. Her clinical expertise encompasses Monkeypox, Smallpox, Rabies, and Ebola Virus Disease.

Frequently Asked Questions about Dr. Melhem M. Solh

How do I make an appointment with Dr. Melhem M. Solh?

You can book an appointment with Dr. Melhem M. Solh by calling their office at 404-255-1930. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Melhem M. Solh a top-rated expert for Acute Myeloid Leukemia (AML)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Melhem M. Solh is classified as an Elite expert for Acute Myeloid Leukemia (AML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Melhem M. Solh specialize in?

While Dr. Melhem M. Solh is a Internal Medicine, they have specific expertise in Acute Myeloid Leukemia (AML), Leukemia, and Graft Versus Host Disease (GvHD). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Melhem M. Solh participate in research or clinical trials?

Yes. Dr. Melhem M. Solh has published 150 articles and abstracts on conditions like Acute Myeloid Leukemia (AML). You can view a list of Dr. Melhem M. Solh's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Melhem M. Solh accept my insurance?

Dr. Melhem M. Solh accepts most major insurance plans, including Absolute Total Care South Carolina and Aetna. We recommend calling the office directly at 404-255-1930 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Solh's expertise for a condition
ConditionClose
View All 10 Distinguished Conditions
View All 9 Advanced Conditions
View All 42 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile